Stavart Louis, Halfon Matthieu, Dewarrat Natacha, Rotman Samuel, Golshayan Dela
Transplantation Center and Transplantation Immunopathology Laboratory, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Front Med (Lausanne). 2024 Aug 29;11:1451264. doi: 10.3389/fmed.2024.1451264. eCollection 2024.
The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after transplantation is still unclear and only based on few case series and reports. Therefore, we aimed to contribute to this understanding by reporting the first documented case of a clinically significant CLL with biopsy-proven infiltration of the kidney allograft and its successful management with a Bruton tyrosine kinase inhibitor (BTKi). We then reviewed the related literature, with a focus on CLL and kidney transplantation. Our main message is that BTKi may represent a safe and effective intervention to prevent the hazardous patient and graft outcomes of CLL in SOT patients.
慢性淋巴细胞白血病（CLL）对实体器官移植（SOT）受者预后的影响似乎不可忽视。既往患有CLL的患者进行移植是否安全，以及移植后最佳的监测和治疗管理是什么，目前仍不清楚，且仅基于少数病例系列和报告。因此，我们旨在通过报告首例经活检证实肾移植受者存在具有临床意义的CLL浸润且使用布鲁顿酪氨酸激酶抑制剂（BTKi）成功治疗的病例，来增进对此的了解。然后，我们回顾了相关文献，重点关注CLL与肾移植。我们的主要观点是，BTKi可能是一种安全有效的干预措施，可预防SOT患者中CLL对患者和移植物造成的不良后果。
